The Trump administration canceled 181 National Cancer Institute grants totaling more than $317 million, and a new report from the American Association for Cancer Research finds that 93% of cancer disparity researchers say federal funding changes have disrupted their work. These aren't abstract budget line items. They are the researchers trying to figure out why Black women die from breast cancer at 35% higher rates than white women, and why rural Americans are 18% more likely to die from cancer overall. The funding stopped. The patients didn't stop getting cancer.
What Got Cut, Exactly
The numbers are not subtle. According to data published in JAMA Oncology last November, the Trump administration canceled 181 grants from the National Cancer Institute in roughly the first half of 2025 alone. Those grants totaled more than $317 million. Many of them specifically studied why cancer hits certain populations harder than others and what can be done about it.
And the NCI wasn't the only target. Thousands of grants across the NIH were terminated throughout 2025, according to Grant Witness, a nonprofit that tracks changes to scientific agency funding. The justification, spelled out in an executive order from January 2025, was that the research was "radical" and "wasteful" DEI work. That framing tells you everything you need to know about how this administration understands the phrase "public health."
The AACR report drew on a survey of 122 researchers across the field, including professors, scientists, and students. Seventy-eight percent said they've been unable to apply for new funding. Fifty-nine percent said ongoing research projects were disrupted. And 59% said the funding they lost came directly from the NIH. This wasn't a rounding error or a budget oversight. It was a policy choice, made deliberately, with predictable consequences.
Trials Stopped. Patients Left Behind.
Here is the part that should make your jaw drop. Mariana Stern, professor of preventive medicine and urology at the Keck School of Medicine at USC and chair of the AACR report committee, told NPR that "many medical trials were stopped in the middle, meaning those patients suddenly didn't receive the treatments they were getting, because the funding stopped."
Read that again. Patients who were actively enrolled in cancer treatment trials had those trials cut out from under them. Not because the science failed. Not because the treatments weren't working. Because an executive order decided the research was ideologically inconvenient.
This is not a policy disagreement about grant priorities. This is the federal government pulling the chair out from under sick people mid-sit.
Fifty-Three Years of Funding, Gone in a Slash
Scarlett Lin Gomez, a professor of epidemiology and biostatistics at UC San Francisco, runs the Greater Bay Area Cancer Registry. The NCI has funded that registry for 53 consecutive years. As NPR reports, Gomez says the cut her program received was "completely unprecedented" in all those years. Nothing close to this magnitude. Not once.
Gomez runs a lab of about 50 people. She had to let go of roughly seven full-time employees last year and expects to cut five or six more this year. "It literally keeps me up at night," she told NPR. "I'm hearing from colleagues over the past several months that everybody's looking at doing the same thing. It's scary to even think about what that's going to look like."
Fifty-three years of institutional knowledge. Databases built across generations of researchers. Community relationships that take decades to develop. The kind of trust that makes it possible to recruit patients from communities that have every historical reason not to trust medical institutions. You can't rebuild that in a budget cycle. You can't undo that damage with a press release when the political winds shift.
The Administration's Defense Is Embarrassing
Asked about cuts to cancer disparities funding, the NIH sent NPR a statement saying that "NCI identifies cancer disparity research as a priority" and that advancements in the field "generate knowledge benefiting all patients across the cancer continuum."
So the agency overseeing the program is on record saying this research is a priority. The same agency that canceled $317 million worth of it. The same agency that terminated grants at a scale Heather Pierce, senior director for science policy at the Association of American Medical Colleges, called completely unprecedented. Pierce told NPR that under prior administrations, termination was "reserved as a very extreme remedy." Now it's a first-pass management tool.
The NIH's statement is not a defense. It's an alibi. And not a very good one.
Who Actually Pays the Price
Dr. Robert Winn, cancer center director at the Fox Chase Cancer Center in Pennsylvania, was blunt with NPR about what happens when this research slows down. "If we take our foot off the pedal of disparities research, there will be more Americans, in rural communities and others not near centers of excellence, who will not do well."
"Not do well" is doctor-speak for "die from cancers that were preventable or treatable with better information." Rural Americans, Black Americans, communities without access to major research hospitals. These are the people who benefit most from disparity research, and who have the least political power to fight back when it gets cut.
Stern herself had to reword funding applications and, in some cases, change the actual focus of her research to stay compliant and keep her grants alive. She previously received federal funding to train students from racial and ethnic minority backgrounds for careers in medicine and research. That program is gone now. Her reasoning for why it mattered is worth quoting directly: the data show patients do better when treated by people who share their background and understand their culture, and research moves faster when teams are diverse. You don't have to believe that on ideological grounds. The data just says so.
The Dingo Take
Let's be clear about what the Trump administration actually did here. They looked at a body of federally funded science specifically designed to figure out why Americans in rural communities and communities of color die from cancer at higher rates, research that has already helped close those gaps over decades, and they labeled it radical DEI waste. Then they canceled $317 million worth of it, stopped active patient trials mid-treatment, and forced researchers who have spent careers building irreplaceable datasets and community trust to lay off staff and gut their programs.
The NIH wants credit for "identifying cancer disparity research as a priority" while the administration it reports to burns that research to the ground. You don't get to claim a priority while eliminating the funding for it. That's not a policy position, it's a lie dressed up in bureaucratic language, and the only people who suffer for it are the ones who were already suffering more to begin with.
There is no punchline here. A 53-year-old cancer registry got gutted. Patients in active trials lost access to treatment. Seven researchers at one lab lost their jobs, with five or six more on the way. And the communities least equipped to absorb those losses, rural Americans, Black Americans, people far from the centers of excellence, will bear the cost in worse outcomes, later diagnoses, and preventable deaths. This is what it looks like when a government decides that equity is the problem.
